Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSCW) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $4.2 million.

  • Ensysce Biosciences' Operating Expenses rose 5263.29% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 4466.44%. This contributed to the annual value of $11.9 million for FY2024, which is 778.87% down from last year.
  • Per Ensysce Biosciences' latest filing, its Operating Expenses stood at $4.2 million for Q3 2025, which was up 5263.29% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Operating Expenses ranged from a high of $18.1 million in Q3 2021 and a low of $774849.0 during Q1 2021
  • In the last 5 years, Ensysce Biosciences' Operating Expenses had a median value of $3.4 million in 2023 and averaged $4.5 million.
  • In the last 5 years, Ensysce Biosciences' Operating Expenses skyrocketed by 136765.82% in 2021 and then tumbled by 6438.07% in 2022.
  • Ensysce Biosciences' Operating Expenses (Quarter) stood at $3.6 million in 2021, then soared by 109.61% to $7.6 million in 2022, then tumbled by 51.92% to $3.7 million in 2023, then soared by 32.95% to $4.9 million in 2024, then dropped by 13.24% to $4.2 million in 2025.
  • Its Operating Expenses was $4.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.3 million in Q1 2025.